| ²é¿´: 1803 | »Ø¸´: 101 | |||
[½»Á÷]
¡¾×ª×ÔÒ©¶ÉÍø¡¿Teva ±¨¸æÁËÀÖ¹ÛÏø´ÁÙ´²3ÆÚÆÀ¹À½á¹û
|
|||
|
Teva ¶ÔÁÙ´²3ÆÚÆÀ¹ÀÁ˶ÔÓÚÏø´»¼Õ߸ɷÛÎüÈëÆ÷ (MDPIs)ÎüÈëFluticasone Propionate /SalmeterolºÍ¶à¼ÁÁ¿Fluticasone Propionate µÄʵÑéЧ¹û£¬ÊµÑéÊý¾ÝºÜºÃ¡£Ñо¿±íÃ÷ͨ¹ýʹÓøɷÛÎüÈëÆ÷ (MDPI)£¬µÍ¼ÁÁ¿Ó밲ο¼ÁÏà±È¾ßÓиü´óµÄЧÄÜ£¬½á¹ûչʾ Teva À©´óºôÎüµÄÑз¢ÄÜÁ¦ºÍÖ§³ÖÆäºËÐÄ£¬ºôÎüÇý¶¯MDPIƽ̨µÄ·¢Õ¹¡£×î³õµÄ½á¹ûÏÔʾfluticasone propionate/salmeterol MDPIµÄ²»Á¼Ê¼þ¿ÉÒÔºÍfluticasone propionateÖÎÁƺͰ²Î¿¼ÁæÇÃÀ¡£ Ïà¹ØÔĶÁ£º Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva¡¯s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. ¡°These data support Teva¡¯s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,¡± said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. ¡°With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.¡± Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. ¡°We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,¡± said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. ¡°We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.¡± Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
» ²ÂÄãϲ»¶
µ÷¼ÁÇóÊÕÁô
ÒѾÓÐ6È˻ظ´
272·Ö²ÄÁÏ×ÓÇóµ÷¼Á
ÒѾÓÐ36È˻ظ´
275Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ19È˻ظ´
²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ33È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸¹þ¹¤´ó 085600 277 12²Ä¿Æ»ùÇóµ÷¼Á
ÒѾÓÐ17È˻ظ´
»¹Óл¯¹¤¶þÂÖµ÷¼ÁµÄѧУÂð
ÒѾÓÐ47È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
´óÁ¬´óѧ-ÁùÅÌˮʦ·¶Ñ§ÔºÁªºÏÅàÑøÑо¿Éú½ÓÊÕµ÷¼Á
+2/288
½Î÷ʦ´ó»¯Ñ§¹¤³ÌѧԺµ÷¼Á½ñÍí0µã¿ª·Å£¡ ȱ¶î100¸ö£¬Ëٳ壡
+1/87
ÖйúË®²ú¿ÆÑ§Ñо¿Ôº»Æº£Ë®²úÑо¿ËùÕÅÐñÖ¾¿ÎÌâ×éÕÐÆ¸ ¿É´©´÷´«¸ÐÆ÷Ñо¿ ¿ÆÑÐÖúÀí
+1/83
ºÓÄÏũҵ´óѧÀíѧԺ·ÂÉúÓ¦Óû¯Ñ§´´ÐÂÍŶÓÕÐÊÕ˶ʿµ÷¼ÁÉú
+1/56
2026ÄêÄþµÂʦ·¶Ñ§ÔºÐÂÄÜÔ´Óë²ÄÁÏѧԺ˶ʿÑо¿Éúµ÷¼Á¹«¸æ£¨µÚÈýÅú£©
+2/44
´óÁ¬¹¤Òµ´óѧ·ÄÖ¯¿ÆÑ§Ó빤³Ì½ÓÊÕ˶ʿµ÷¼Á
+1/40
Î人¹¤³Ì´óѧ»¯Ñ§Óë»·¾³¹¤³ÌѧԺ2026Äê˶ʿÑо¿Éúµ÷¼Á¹«¸æ
+1/13
Õã½Å©ÁÖ´óѧ ÁÖÒµÓëÉúÎï¼¼ÊõѧԺ ÉúÎïѧ(ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧ) µÚ¶þÂÖµ÷¼ÁÉúÕÐÉú
+1/13
ÖØÇ칤ÉÌ´óѧ ½ÌÓý²¿Ñо¿ÖÐÐÄÕÐÊÕ»¯¹¤/»·¾³/²ÄÁÏ/ʯÓÍ/»¯»ú·½Ïò2026Äêµ÷¼ÁÑо¿Éú
+1/12
ºþÄÏʦ·¶´óѧҩÎï·ÖÎöѧ2026Äê˶ʿÑо¿Éúµ÷¼Á
+1/11
̫ԿƼ¼´óѧ¹âѧ¹¤³Ìѧ¿Æ½ÓÊܵ÷¼Á
+1/11
ºþÄÏÀí¹¤´óѧµ÷¼ÁϵͳÒÑ¿ª¡£ »¯Ñ§¡¢»¯¹¤¡¢²ÄÁÏ»¯¹¤ µ÷¼ÁÖ¸±ê³ä×㣬¼ȡÂʸߣ¬»¶Óµ÷¼Á
+1/10
Äϲýº½¿Õ´óѧ ²ÄÁÏѧԺ ÕвÄÁÏÀàµ÷¼ÁÑо¿Éú£¬Ãû¶î¶à£¬Éϰ¶»ú»á´ó
+1/8
¡¾2026¿¼Ñе÷¼Á¡¿Õã½ÍòÀïѧԺ¹ú¼Ò¼¶ÇàÄêÈ˲ÅÍŶÓ-﮵ç/µç´ß»¯·½ÏòÕÐÊÕµ÷¼ÁÉú
+1/5
½Î÷Ë®ÀûµçÁ¦´óѧÊÐÕþ¹¤³Ì½ÓÊܵ÷¼Á
+1/4
ÖØÇ칤ÉÌ´óѧ ½ÌÓý²¿Ñо¿ÖÐÐÄÕÐÊÕ»¯¹¤/»·¾³/²ÄÁÏ/ʯÓÍ/»¯»ú·½Ïò2026Äêµ÷¼ÁÑо¿Éú
+1/4
Çൺ´óѧ˶ʿµ÷¼Á£¨ÎïÀí/²ÄÁÏ£¬¼ÆËãÄ£Äâ·½Ïò£¬»¶ÓÁªÏµ£©
+1/3
ÉϺ£Ó¦Óü¼Êõ´óѧ»¯¹¤Ñ§²¿ÕÐÉúµ÷¼Á
+1/3
±±¾©Å©Ñ§ÔºÖ²Îï±£»¤ÕÐÊÕ1Ãûѧ˶
+1/3
º«¹úººÑô´óѧÊ×¶ûÐ£ÇøADIPʵÑéÊÒ³ÏÕв©Ê¿ºó
+1/2
¡ï
Ò©¶É(½ð±Ò+1): лл²ÎÓë
Ò©¶É(½ð±Ò+1): лл²ÎÓë
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
14Â¥2015-11-20 16:01:12
¼òµ¥»Ø¸´
sxln2Â¥
2015-11-20 15:48
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
laom20133Â¥
2015-11-20 15:50
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
miaojiabing4Â¥
2015-11-20 15:50
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
10357505705Â¥
2015-11-20 15:50
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
¡£ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
ÌìÑÄ20126Â¥
2015-11-20 15:51
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
skyish7Â¥
2015-11-20 15:52
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
laozhu55728Â¥
2015-11-20 15:54
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
dmbb9Â¥
2015-11-20 15:57
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
½ÄϵÄÖñ10Â¥
2015-11-20 15:58
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
¡£ [ ·¢×ÔСľ³æ¿Í»§¶Ë ]
chenchenyf11Â¥
2015-11-20 15:59
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

xiejiaf12Â¥
2015-11-20 16:00
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

feiyief13Â¥
2015-11-20 16:01
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

mhycpxir15Â¥
2015-11-20 16:01
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

irshvj16Â¥
2015-11-20 16:02
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

kolimm17Â¥
2015-11-20 16:02
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
am435918Â¥
2015-11-20 16:02
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
wblxcs19Â¥
2015-11-20 16:02
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
wnotffisg20Â¥
2015-11-20 16:03
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
ahsjlyu21Â¥
2015-11-20 16:03
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
.
keoxri22Â¥
2015-11-20 16:03
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

vrxcyvkss23Â¥
2015-11-20 16:03
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
,
ooxmfc24Â¥
2015-11-20 16:04
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

ucmxjl25Â¥
2015-11-20 16:04
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
,
bincmq26Â¥
2015-11-20 16:04
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
fqmkia27Â¥
2015-11-20 16:04
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
wxubpn28Â¥
2015-11-20 16:05
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
iygbojqj29Â¥
2015-11-20 16:05
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

sjtdeud30Â¥
2015-11-20 16:05
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

shsvoy31Â¥
2015-11-20 16:05
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
cmyfna32Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

sgadsdkc33Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
,
quainyni34Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

wbwwrs35Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
yuduoj36Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

Ö§³Ö
ofresq37Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
.
tanmingp38Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

qdjoupudwqx39Â¥
2015-11-20 16:06
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
,
qyoycw40Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
fangfengw41Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
virologik42Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
liufeic43Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

xiachaz44Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

hodydo45Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

zhangfangp46Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

hudouz47Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
×£¸£
ffwmeg48Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë
.
yushat49Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

qiyingy50Â¥
2015-11-20 16:07
»Ø¸´
Ò©¶É(½ð±Ò+1): лл²ÎÓë

Ö§³Ö



»Ø¸´´ËÂ¥